Comparative evaluation of marketed formulations of Metformin HCl. available in India

Background: The aim of this review is to compare the efficacy of liraglutide versus sitagliptin add-on-to metformin in patients with Type 2 Diabetes Mellitus and inadequate glycemic control for rational use of drugs. Methods: We searched for randomized controlled trials (RCT) in MEDLINE, Web of science, PubMed, Cochrane library, CNKI, and Wanfang database and extracted data from all randomized controlled trials (RCTs) up to July 11, 2019 of liraglutide versus sitagliptin given in combination with metformin. RCTs were selected only if they were RCTs comparing DPP-4 inhibitor (sitagliptin) monotherapy to metformin monotherapy with the GLP-1 Receptor Agonists (liraglutide), duration of treatment was ≥26 weeks and reported data on hemoglobin A1c (HbA1c) change, fasting plasma glucose (FPG) change, Odds ratio (OR), mean difference (MD), 95% confidence interval are used to analyze the outcomes. Results: A total of 2,257 patients from 6 RCTs were included in the study. When compared with sitagliptin (100mg) in combination with metformin group, the group of patients treated with liraglutide1.2mg and 1.8mg and metformin, produced greater reduction in HbA1c, FBG. (95% CI). The group of patients with 1.8mg liraglutide had significant weight loss. The incidence of nausea, hypoglycemic episodes, gastrointestinal problems was higher than the sitagliptin with metformin groups. Conclusions: The results of this study indicated that the liraglutide – metformin combination therapy could significantly lower the HbA1c level and increased reduction of body weight. ADRs such as gastrointestinal problems, hypoglycemic episodes were common in liraglutide treatment group.

show abstract

A Review: Comparison of Efficacy of Liraglutide Versus Sitagliptin add-on-to Metformin in Type 2 Diabetes Mellitus patients

Kavyasree

Geetha

Shanmugasundaram

2021

RJPT

View full text Add to dashboard Cite

show abstract

Development of new Validated HPTLC Method for simultaneous estimation of Canagliflozin and Metformin in Tablet Formulation

Vichare¹,

Choudhari

Reddy³

2022

RJPT

View full text Add to dashboard Cite

A new HPTLC method for simultaneous determination of Canagliflozin and Metformin was developed, validated and compared with the reported one. An excellent resolution with Rf values 0.21±0.02 and 0.50±0.03 for Metformin and Canagliflozin respectively was achieved by using optimized chromatographic conditions. Toluene: Methanol: Triethyl amine: Glacial Acetic acid (7:2.6:0.2:0.2, v/v/v/v) was chosen as a mobile phase. Detection was done at 254nm. When marketed formulation was analyzed by developed method, the % drug contents were found to be 98.20±0.24 and 99.33±1.80% w/w for Metformin and Canagliflozin respectively. Developed method was validated for linearity and range, DL, QL, accuracy, precision, robustness and specificity. The method was found to be linear, accurate, precise, robust and sensitive. The method was found to be linear in a range of 75-750ng/band of Canagliflozin with R2 value 0.9981 and 250-2500ng/band of Metformin with R2 value 0.9963. Detection and quantitation limits were found to be 8.01 and 24.28ng/band for Metformin and 8.27 and 25.07ng/band for Canagliflozin respectively. The % drug recovery was calculated as a measure of accuracy. The % drug recovery was found to be near to 100 %w/w confirmed the accuracy of the method. In case of precision studies, %RSD values were found to be less than two indicated, the method is precise. The % RSD values of deliberate variations like amount of mobile phase, saturation time were found to be less than two showed method is robust. The developed method was compared with the reported method and found to be more linear, accurate, precise and sensitive.

show abstract

Vitamin D as add on Therapy to Metformin and Teneligliptin in patients with type 2 Diabetes Mellitus

Ahmad Khan,

Chandra,

Lal Kanojia

2023

RJPT

View full text Add to dashboard Cite

A low level of vitamin D is being attributed to the development of diabetes, which can cause insulin resistance, beta-cell death, and inflammation. Vitamin D supplementation can reduce inflammation and insulin resistance. we conducted this study for our population to evaluate the effect of vitamin D on blood glucose in type 2 diabetes mellitus. A prospective interventional, parallel, randomized study, was conducted on 112 type two diabetes and 25(OH) D deficient patients. The control group received Metformin (500mg BD) and Teneligliptin (20mg OD) only, while the intervention group was given Metformin plus Teneligliptin along with vitamin D (Cholecalciferol) (60,000 IU). At the end of 3rd of month follow-up, there was a significant difference in mean FPG and PPG (129.86±7.36mg/dl) vs. (136.12±11.31mg/dl) (p=0.002), (220.81±13.04mg/dl) vs. (228.06±19.40 mg/dl) (p=0.037). in the interventional and control group respectively. And subsequently, mean HbA1c improved significantly in the interventional group as compared to the control group 7.21±0.40% vs. 7.48.0.62% respectively (p = 0.015). also, the measures of glycemic control (FPG, PPG, HbA1c) showed a significant improvement at the end of the 6 months. Our study suggested, that add-on therapy of Vitamin D improved the glycemic parameters of type two diabetes mellitus with concurrent vitamin D deficiency over the course of the study.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Comparative evaluation of marketed formulations of Metformin HCl. available in India

Cited by 4 publications

References 0 publications

A Review: Comparison of Efficacy of Liraglutide Versus Sitagliptin add-on-to Metformin in Type 2 Diabetes Mellitus patients

A Review: Comparison of Efficacy of Liraglutide Versus Sitagliptin add-on-to Metformin in Type 2 Diabetes Mellitus patients

Development of new Validated HPTLC Method for simultaneous estimation of Canagliflozin and Metformin in Tablet Formulation

Vitamin D as add on Therapy to Metformin and Teneligliptin in patients with type 2 Diabetes Mellitus

Contact Info

Product

Resources

About